Business EconomyPosted at: Oct 14 2025 12:14AM


Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy

Hyderabad, Oct 13 (UNI) Bristol Myers Squibb (BMS) today announced the launch of Kopozgo® (Mavacamten) in India -- the first and only oral, selective cardiac myosin inhibitor approved in the country for the treatment of adults with symptomatic New York Heart Association (NYHA) Class II–III obstructive hypertrophic cardiomyopathy (OHCM).
Symptomatic obstructive HCM is an often-inherited heart disease that can be a chronic, debilitating and progressive condition where patients may experience symptoms of shortness of breath, dizziness and fatigue as well as serious, life-altering complications, including heart failure, arrhythmias, stroke and in rare cases (~1%) sudden cardiac death.
It affects about 1 in 500 people worldwide, and it is estimated that as many as 2.8 million people in India may be living with the condition; however, 80-90 % patients remain undiagnosed.
Existing medical treatments in India, such as beta blockers, calcium channel blockers, and disopyramide, reduce symptoms but do not address the underlying cause.
Kopozgo is the first in-class disease-specific treatment targeting the core pathophysiological mechanism of obstructive HCM, leading to improvement in functional capacity of heart and symptoms.
Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO) with an import license issued on March 6, 2025.
Kopozgo is now available to patients in India.
The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM.
Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, “With the launch of Kopozgo in India, patients with oHCM now have a promising first-in-class treatment option. This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care for patients in India.”
Globally, mavacamten has been widely recognized, with its first approval granted by the U.S. Food and Drug Administration (FDA) on April 28, 2022, followed by approval from the European union on June 26, 2023.
Since then, the medicine has continued to expand its reach, receiving marketing authorization in more than 50 countries, underscoring its global significance as a breakthrough therapy for symptomatic obstructive hypertrophic cardiomyopathy. UNI KNR SS
Please log in to get detailed story.
Tags: #Bristol Myers Squibb launches Kopozgo in India for treatment of symptomatic Obstructive Hypertrophic Cardiomyopathy
More News

08 Nov 2025 | 2:16 AM

Hyderabad, Nov 7 (UNI) With India’s MedTech industry valued at USD14 billion, expected to grow at 14 per cent annually, Venugopala Rao Sankineni, Vice President – Medical Devices Policy & Investments, Telangana Lifesciences, Government of Telangana, on Friday pointed out that 70% of medical devices are still imported, underscoring the need for domestic manufacturing.

see more..

Credit card spend increased 23 pc in September to Rs 2 17 lakh crore

08 Nov 2025 | 1:04 AM

Chennai, Nov 7 (UNI) The swiping of credit cards for spending increased by 23 percent in September 2025 year-on-year (y-o-y) and by 13 percent sequentially to Rs 2.17 lakh crore, said credit rating agency CARE Ratings.

see more..

Partners Group completes acquisition of Infinity Fincorp

08 Nov 2025 | 12:26 AM

Chennai, Nov 7 (UNI) Non-banking finance company (NBFC) Infinity Fincorp Solutions, focused on India’s micro, small, and medium enterprises (MSME) sector, on Friday announced the completion of its acquisition by Partners Group, one of the largest firms in the global private markets industry, acting on behalf of its clients as a majority investor.

see more..

'Each country entitled to its right share of tax' says official while urging for appropriate policies

07 Nov 2025 | 8:39 PM

New Delhi, Nov 7 (UNI) Raman chopra, principal chief commissioner of Income Tax, said on Friday that each country is entitled to its right share of tax in respect of every international transaction.

see more..

Kottayam-Kochi Rubber Market Rates

07 Nov 2025 | 7:31 PM

Kottayam Nov 7 (UNI) Following were the Rubber Market rates announced by the Rubber
Board here today per quintal.

see more..